Anti-adalimumab and anti-certolizumab antibodies titers after discontinuation of adalimumab: two case reports.

It has been shown that in patients with rheumatoid arthritis, switched to a second anti-TNF drug for the development of ADAs against the starting agent, the clinical outcome may significantly ameliorate, even better than in patients not developing ADAs [7]. The immunogenicity to the first anti-TNF therapy determines the outcome of switching to a second anti-TNF therapy in spondyloarthritis patients. [Extracted from the article]